EXECUTION OF THE PROJECT FOR THE REDEFINITION OF THE CORPORATE STRUCTURE OF DIASORIN

Saluggia, June 7, 2022 – DiaSorin S.p.A. (FTSE MIB: DIA) (“DiaSorin” or the “Company”) informs that the project for the redefinition of the corporate structure of DiaSorin, which was already approved by the Board of Directors of DiaSorin and communicated to the market on December 16, 2021 and on May 6, 2022, was executed today.

As previously stated, the main objective of the project is to align DiaSorin’s corporate structure with the Group’s organizational development and multinational profile, and its implementation is envisaged through the contribution in kind of the branch of business of DiaSorin (the “Branch”) related to the operating activities carried out in Italy and in the United Kingdom – the latter, through a branch – (i.e., industrial activities, R&D, commercial and marketing activities and those other ancillary activities in support thereof) in favour of DiaSorin Italia S.r.l. (“DiaSorin Italia”), a wholly-owned direct subsidiary of the Company (collectively, the “Contribution”).

Following completion of the Contribution, DiaSorin will continue to be in charge of the definition and the development of the strategic orientation, treasury and coordination activities for the benefit of the entire Group, while the management of the operating activities currently carried out by the Company in Italy and in the United Kingdom will be delegated to DiaSorin Italia (similarly to the current practice in place with the subsidiaries operating in the other geographical areas).

In particular, the shareholders’ meeting of DiaSorin Italia was held today to approve (i) a share capital increase against payment for a nominal value of Euro 990,000.00 and share premium of Euro 352,500,219.00 and, as such, for an aggregate price equal to Euro 353,490,219.00, reserved for subscription to DiaSorin, as sole shareholder, to be fully subscribed and paid in through the Contribution, and (ii) the transformation of DiaSorin Italia in a joint stock company (società per azioni) with the new denomination “DiaSorin Italia S.p.A.” and the consequent adoption of a new corporate bylaws. Also today, DiaSorin and DiaSorin Italia stipulated the notarial deed relating to the Contribution.

The above resolutions and the deed of Contribution will become effective as of July 1, 2022 (the “Effective Date”), subject to registration with the competent Companies’ Register.

Therefore, as at the Effective Date DiaSorin Italia will acquire ownership of the Branch and will have a share capital of Euro 1,000,000.00 represented by 1,000,000 shares, without nominal value, entirely held by DiaSorin.

Conclusively, it is hereby announced that the shareholders’ meeting of DiaSorin Italia held today resolved on the appointment, effective as of the Effective Date, of a board of directors composed of five members, a board of statutory auditors composed of three standing members and two alternate members, as well as the external auditor. The corporate bodies will remain in office until the date of approval of the financial statements as at December 31, 2024.

For additional information, please contact:

**Riccardo Fava**
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

**Emanuela Salvini**
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it
About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”. More info at www.diasoringroup.com